PSQ Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PSQ Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.69M | Mar 14, 2024 |
| FY2023 | Dec 31, 2022 | $475.2K | Mar 14, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.22M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $10.06M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.69M | Mar 13, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.61M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($57.69M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($53.33M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($6.98M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $3.73M | Mar 24, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.96M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($41.70M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($39.35M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($7.10M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($852.2K) | Mar 24, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.84M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.89M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $4.63M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.45M | Mar 14, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.94M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($34.13M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($25.76M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($6.03M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($973.5K) | Mar 24, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | $113.1K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $29.9K | Mar 14, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.68M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $74.89M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $25.25M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $4.22M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $173.95M | Mar 24, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.24M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $48.04M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $14.81M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $814.3K | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $12.60M | Mar 24, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.44M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $26.85M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $10.43M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $3.40M | Mar 13, 2025 |
| FY2023 | Jan 1, 2022 | $860.5K | Mar 14, 2024 |
| FY2023 | Dec 31, 2021 | $860.5K | Mar 14, 2024 |
| FY2021 | Feb 11, 2021 | $0 | Mar 22, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.93M | Mar 17, 2026 |
| FY2025 | Oct 1, 2025 | $10.90M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $10.93M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 13, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($156.51M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($119.90M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($62.21M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($8.88M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($11.15M) | Mar 24, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.64M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $35.73M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $16.45M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.33M | Mar 14, 2024 |
| FY2021 | Dec 31, 2021 | $841.2K | Mar 22, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |